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RESEARCH ARTICLE
The Danish Neuro-Oncology Registry: 
establishment, completeness and validity
Steinbjørn Hansen1,2*, Jan Nielsen3, René J. Laursen4, Birthe Krogh Rasmussen5, Bente Mertz Nørgård3, 
Kim Oren Gradel3 and Rikke Guldberg3
Abstract 
Background: The Danish Neuro-Oncology Registry (DNOR) is a nationwide clinical cancer database that has pro-
spectively registered data on patients with gliomas since January 2009. The purpose of this study was to describe the 
establishment of the DNOR and further to evaluate the database completeness of patient registration and validity of 
data.
Methods: The completeness of the number of patients registered in the database was evaluated in the study period 
from January 2009 through December 2014 by comparing cases reported to the DNOR with the Danish National 
Patient Registry and the Danish Pathology Registry. The data validity of important clinical variables was evaluated by a 
random sample of 100 patients from the DNOR using the medical records as reference.
Results: A total of 2241 patients were registered in the DNOR by December 2014 with an overall patient complete-
ness of 92 %, which increased during the study period (from 78 % in 2009 to 96 % in 2014). Medical records were 
available for all patients in the validity analyses. Most variables showed a high agreement proportion (56–100 %), with 
a fair to good chance-corrected agreement (k = 0.43–1.0).
Conclusions: The completeness of patient registration was very high (92 %) and the validity of the most important 
patient data was good. The DNOR is a newly established national database, which is a reliable source for future scien-
tific studies and clinical quality assessments among patients with gliomas.
Keywords: Brain neoplasms, Glioma, Validity, Completeness, Database research, Clinical quality indicators
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The Danish Neuro-Oncology Group (DNOG) is the Dan-
ish Multidisciplinary Cancer Group for adult patients 
with primary brain tumors. The DNOG develops guide-
lines recommending procedures for the diagnostic 
process and treatment in patients with brain tumor in 
Denmark. In an extension, a national clinical database 
was established to monitor the quality of treatment and 
the changes in the clinical practice. Hence, the Dan-
ish Neuro-Oncology Registry (DNOR) was established 
under the auspices of DNOG and it has prospectively 
registered nationwide data on patients with gliomas since 
January 2009 [1].
In 2014, about 1500 newly diagnosed patients with 
neoplasms in the brain, meninges and cranial nerves 
were registered in Denmark according to the National 
Cancer Registry (NCR). These tumors are a heterogene-
ous entity of many different tumor types [2]. The glioma 
is the most common tumor type in adult primary brain 
tumor patients. Additional to the registration in NCR 
these patients have been registered with clinical data in 
the DNOR. Patients with glioma have a life threatening 
disease, which requires prompt handling from the health 
care providers. This disease has major implications for 
the patients and their families’ quality of life. Health 
care costs are high including complicated neurosurgi-
cal operations and technically advanced radiotherapy, as 
well as expensive chemotherapy. For many of the patients 
there may be a need for rehabilitation or nursing home 
care. DNOR is thus a quality clinical database of high 
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relevance, and DNOR publishes annual reports with key 
clinical quality indicators. This enables to compare own 
results to pre-specified standards and to detect changes 
in own results from year to year. These results can also 
be compared to the reported national levels and regional 
differences can be detected. The discussion of the results 
from the annual report is an integrated part of the work 
in DNOG on updating the national guidelines.
The DNOR provides a systematic prospective collec-
tion of clinical data, which ensures an important source 
for optimizing clinical practice and for scientific inves-
tigations. However, the scientific utility requires suf-
ficient completeness of patient registration and high 
data validity. The purpose of this study was to describe 
the establishment of the DNOR, to evaluate the patient 
completeness using central health service registries as 
the reference, and to determine the validity of the most 




The DNOR was established by the DNOG and is finan-
cially supported by the health care authorities through 
the Danish Clinical Quality Improvement Program. 
DNOR is organized with a steering committee of spe-
cialists in neurosurgery, medical and radiation oncol-
ogy, neurology, neuroradiology and pathology, as well as 
representatives from the Competence Centre for Clini-
cal Epidemiology and Biostatistics, South, Competence 
Centre for Health Quality and Informatics, and from 
the Region of Southern Denmark housing the database 
through the Department of Oncology, Odense University 
Hospital.
It is mandatory for all departments of neurosurgery 
and oncology, treating patients with glioma, to report 
data to the DNOR. Initially, five surgical and six onco-
logical departments participated; this is now reorganized 
to four neurosurgical and four oncological departments 
representing the departments treating patients with gli-
oma in Denmark. The data input is web-based through 
a secured health care network. The data model is organ-
ized in four parts (Fig. 1). Each patient has one data form 
for primary diagnostics, followed by three optional data 
forms for neurosurgery, radiation therapy, and chemo-
therapy, all of which can be repeated upon recurrences. 
The inclusion criteria are patients diagnosed with a pri-
mary glioma (not ependymoma) after 1 January 2009 and 
patients aged ≥18 years at the time of diagnosis.
The data contains information about primary symp-
toms, characteristics of baseline magnetic resonance 
imaging (MRI), performance status, operating proce-
dures, the surgeon’s qualification, post-surgical MRI, 
post-surgical complications, diagnostic classification 
according to the tenth edition of the International Clas-
sification of Diseases (ICD-10), histologic type according 
the Systematized Nomenclature of Medicine (SNOMED) 
Morphology (M) codes, and characteristics for radio-
therapy and chemotherapy. Eight clinical quality indica-
tors (Table 1) are defined for annual reporting in which 
department-specific proportions can be compared to the 
national levels, pre-specified standards, and followed for 
time trends [3].
Patient completeness
Each Danish citizen is identified by a 10-digit code 
including information about sex and date of birth, which 
is registered in the Danish Civil Registration System [4]. 
This unique personal identification number is recorded 
in all public registries including the health service reg-
istries. The National Health Service provides regulated 
free access to health care services facilitating a popula-
tion-based identification of all brain tumor patients in 
Denmark. To obtain mortality data, the DNOR-patients 
are linked to the Danish Civil Registration System on a 
monthly basis. The Danish Civil Registration System 
comprises daily updated data on the patients’ vital status, 
as well as date of death, disappearance, or emigration, if 
relevant [5].
The Danish National Patient Registry (NPR) [6] con-
tains information about the dates of admission and 
discharge, the type of operation, examination, and treat-
ment, as well as the main diagnosis and up to 20 sub-
diagnoses for each discharge. The diagnoses are classified 
according to the ICD-10, and the surgical procedures 
according to the Danish classification system of surgical 
procedures [7]. The Danish National Pathology Registry 
(DPR) [8, 9] contains detailed nationwide records of all 
pathology specimens analyzed in Denmark since 1997.
To assess the patient completeness in the DNOR, 
recordings in both the NPR and the DPR were used as the 
gold standard. For each calendar year in the study period 
(2009–2014), the completeness was computed as the pro-
portion of adult patients in the NPR and the DPR who 
were recorded in the DNOR, using the unique personal 
identification number to link between the registries.
For patients to be included in the gold standard pop-
ulation, three criteria all had to be fulfilled for each cal-
endar year (2009–2014) (1) Age 18  years and older, (2) 
Registered in the NPR with one of the following ICD-10 
codes: D33.0–33.2; D33.7; D33.9; D43.0–43.2; D43.7 + 9; 
C71.0–71.9; C72.8–9, and (3) Registered in the DPR 
with one of the following SNOMED M codes: M93813, 
M93823, M93841, M93853, M94003, M94013, M94113, 
M94213, M94243, M94253, M94403, M94423, M94503, 
or M94513.
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Primary diagnosc (2455)*
(2011) Planned for surgery
(5)       Observaon
(1)       Not fit for surgery
(1)       Other
(7)       Missing
(2012) Primary surgery
(512)   Progression surgery
(6)       Complicaon surgery
(81)     Residual tumour
(1)       Other
(16)     Unknown
(7)       Missing
(1709) Primary RT
(44)     Re-irradiaon
(17)     No RT
(39)     Neoadjuvant
(992)   Concomitant
(795)   Adjuvant
(861)   Progression
(47)     No chemotherapy
(4)       Unknown








Number of forms Number of paents per sub-forms Departments
Fig. 1 Data model of DNOR with the number of forms entered (left) and the distribution of number of patients (middle) within each subtype of 
forms, and departments (right) responsible for entering clinical data into DNOR from 2009 to 2014. Asterisk some of the patients have been regis-
tered with multiple forms
Table 1 Indicators used for annual reporting in the Danish Neuro-Oncology Registry
No. Descriptions Standards (%)
Ia Proportion of patients who are alive 1 year after surgery out of all patients in whom the histological diagnosis is glioblastoma ≥50
Ib Proportion of patients who are alive 2 years after surgery out of all patients in whom the histological diagnosis is glioblastoma ≥15
II Proportion of patients who have undergone postoperative MRI no later than the 3rd day after primary surgery out of all patients 
who have undergone resection and have contrast-enhancing tumor (i.e., suspected high-grade glioma) prior to resection
≥90
III Proportion of operations conducted or supervised by a specialist in neurosurgery out of all operations both primary and at 
progression
≥95
IV Proportion of patients with no measurable residual tumor demonstrated by postoperative MRI performed after primary surgery 
out of all primarily diagnosed patients, where the histological diagnosis is glioblastoma. (Denominator includes patients with 
only performed biopsy or where control MRI scan is not available)
≥20 and
≤70
V Proportion of patients alive more than 30 days after surgery out of all patients who have undergone primary surgery for gliomas ≥95
VI Proportion of patients finishing focal high-dose radiation therapy as planned out of all patients starting this treatment and 
where the histological diagnosis is glioblastoma
≥90
VII Proportion of patients finishing concomitant chemoradiotherapy with temozolomide as planned out of all patients starting this 
treatment and where the histological diagnosis is glioblastoma
≥85
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Validation of clinical variables
We compared the registration of selected variables 
between the DNOR and the medical records. A number 
of 100 patients with neurosurgery performed from 1 Janu-
ary 2013 through 31 December 2013 were randomly sam-
pled from the DNOR. The variables were selected as being 
important according to the preoperative symptoms, diag-
nostic work-up, the surgical procedures, and the postop-
erative treatment (selected variables are listed in Table 3).
Data from the medical records of the 100 patients were 
extracted, collected, and keyed into a validation data-
base by the same person, who was blinded to the original 
DNOR data. The data of the MRI characteristics was cap-
tured from what was written in the radiology report, and 
if missing then from what the neurosurgeon had written 
in the medical report. We did not reevaluate the pictures 
of the MRI if the description of the characteristics was 
missing in the radiology and medical report.
Statistics
The validity was assessed as percent agreement between 
the originally reported data in the DNOR and data in 
medical records, including exact 95  % confidence inter-
vals (CI). The chance-corrected proportional agreement 
was calculated as a kappa coefficient (k) for categorical 
variables. The following qualitative terms were attached 
to the kappa value: poor agreement if k ≤ 0.4, fair to good 
agreement if 0.4  <  k  <  0.75, and excellent agreement if 
k ≥ 0.75 [10].
Approvals
The study was approved by the Danish Data Protection 
Agency (no. 2008-58-0035/14/6151) and by the Dan-
ish Health and Medicine Authority (no. 3-3013-514/1). 
According to Danish law no approval from the Ethics 
Board or patient’s consent is required as the study did not 
require intervention with the patients.
Results
By 31 December 2014, a total of 2241 patients were 
recorded in the DNOR. The departments of neurosur-
gery only have access to open the data forms on primary 
diagnosis and surgery. Departments of oncology only 
have access to data forms on radiotherapy and chemo-
therapy. For 425 patients, only primary diagnosis and/
or surgery were reported, 1606 patients had primary 
diagnosis, neurosurgical and oncological forms, and 210 
patients had only radio- and chemotherapy forms, but no 
information on the primary diagnosis.
Patient completeness in the DNOR
In 2009, 308 of 393 patients in the NPR/DPR (78 %) were 
present in the DNOR, whereas a higher completeness 
(93–97 %) was seen thereafter (Table 2). In the total study 
period, 2241 of 2437 patients (92  %) in NPR/DPR were 
registered in the DNOR.
Validation of clinical DNOR variables
The medical records were available for all 100 patients 
and the observed agreements, and agreements corrected 
for chance agreement (kappa), are shown in Table 3.
Onset symptoms
Debut of focal neurological symptoms, epileptic seizures, 
changes in personality or behavior and cognitive dete-
rioration, and headache may be present either mono-
symptomatically or in combination. These symptoms at 
onset showed satisfying observed agreements on 84 % for 
focal deficit, 90 % for seizure, 76 % for cognitive change, 
and 84  % for headache. We found fair to good chance-
corrected agreements, and especially high for epileptic 
seizures (k = 0.71).
Diagnostic work‑up
The characteristics of the preoperative MRI are used to 
examine the surgical options. Registration of performed 
preoperative MRI showed excellent agreement (100 %; k 
1.0). MRI characteristics had high agreements (91–99 %), 
with fair to good chance-corrected agreements (k 0.49–
0.75). The agreement proportion for the scanning date 
was 84  % and for the bi-dimensional tumor diameter 
56–57 %.
Surgery
The primary surgical procedure is planned to obtain a 
histological diagnosis and to remove as much tumor 
tissue as feasible, evaluated by an early postoperative 
MRI. The dates of operative procedure and postopera-
tive MRI showed high agreements (93–99 %). Satisfying 
agreements were obtained for the surgical procedure 
Table 2 The patient registration completeness in the Dan-
ish Neuro-Oncology Registry (DNOR) using the Danish 
National Patient Register (NPR) and the Danish Pathology 
Registry (DPR) as reference





DNOR DNOR  
completeness
2009 393 85 308 78
2010 414 31 383 93
2011 395 26 369 93
2012 394 21 373 95
2013 413 14 399 97
2014 428 19 409 96
Total 2437 196 2241 92
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code (77  %), the performed postoperative MRI (93  %) 
and residual tumor classification (80  %), which all 
had fair to good chance-corrected agreements (kappa 
0.52–0.72).
Oncology
Residual tumor cells can be treated with radiochemother-
apy in fit patients evaluated by the performance status 
score. Performance status before radio- or chemotherapy 
showed high agreements (91–93  %) with an excellent 
chance corrected agreement (k 0.84–0.87). Treatment 
status had fair to good chance-corrected agreements 
(k 0.43–0.63). The agreements were high for the date of 
onset of radio- or chemotherapy, 87–88 %.
Discussion
The DNOR is a national population-based registry in 
which prospectively recorded clinical data from glioma 
patients in Denmark are registered. The results of this 
study show that the patient completeness of the database 
and the validity of clinical data are satisfactory. The com-
pleteness of the patient registration in the database was 
high and increased by calendar year, from 78 % in the 1st 
year to 96 % in 2014. Although reporting to clinical data-
bases is mandatory by law, a low completeness of new 
clinical databases is not surprising, and is often related 
to lack of tradition for registration within the clinical dis-
ease area. From the start of the DNOR it has been ongo-
ing work to motivate the clinical departments to increase 
Table 3 Agreement between  clinical variables in  the DNOR and  the same information from  the medical records esti-
mated from a random sample of 100 patients
MRI magnetic resonance imaging, DNOR Danish Neuro-Oncology Registry, CI confidence intervals
a Totals in DNOR varies between variables because not all information was available
b Kappa: poor agreement if k ≤ 0.4, fair to good agreement if 0.4 < k<0.75 and excellent agreement if k ≥ 0.75









 Focal deficit 83/99 84 75–90 0.61
 Seizure 89/99 90 82–95 0.71
 Cognitive change 75/99 76 66–84 0.52
 Headache 83/99 84 75–90 0.61
Diagnostic work-up
 Preoperative MRI performed 100/100 100 – 1.0
 Date of preoperative MRI (±1 day) 83/99 84 75–90 –
 Preoperative MRI: number of tumors 92/99 93 86–97 0.75
 Preoperative MRI: contrast enhancement 85/87 98 92–100 0.49
 Preoperative MRI: crossing midline 82/90 91 83–96 0.62
 Preoperative MRI: localization 92/99 93 86–97 0.75
 Preop. MRI: tumor diameter (±5 mm) 51/91 56 45–66 –
 Preop. MRI: orthogonal diam. (±5 mm) 43/75 57 45–69 –
Surgery
 Procedure code of surgery 77/100 77 68–85 0.63
 Date of surgery (±1 day) 99/100 99 95–100 –
 Postoperative MRI performed 93/100 93 86–97 0.72
 Date of postoperative MRI (±1 day) 76/82 93 84–97 –
 Residual tumor on postoperative MRI 65/81 80 70–88 0.52
Radiotherapy
 Performance status before radiotherapy 53/57 93 83–98 0.87
 Date of 1st radiation therapy (±1 day) 88/100 88 80–94 –
 Treatment status, radiotherapy 95/100 95 89–98 0.43
Chemotherapy
 Performance status before chemotherapy 52/57 91 80–97 0.84
 Date of 1st Chemotherapy (±1 day) 80/92 87 78–93 –
 Treatment status, chemotherapy 82/91 90 82–95 0.63
Page 6 of 7Hansen et al. BMC Res Notes  (2016) 9:425 
the completeness. In the beginning, paper forms were sent 
to the departments for registration of data when evalu-
ating the patient, and lists of potential missing patients 
were sent to the departments for review. In 2009, a total 
of 11 departments reported data, but as the treatment has 
been further centralized there are now only eight depart-
ments reporting data to the DNOR. Today, all the relevant 
departments have well-established online registration of 
data.
Exact evaluation of the completeness of clinical quality 
databases is often not possible due to lack of gold stand-
ard data. In Denmark, the unique personal registration 
number, given to all Danish residents, makes it possible 
to link individual patients in clinical quality databases 
to other registries from which a gold standard popula-
tion can be determined. The completeness of the public 
health registries is high, partly due to the free access to 
treatment for all inhabitants and partly because hospi-
tals only obtain public reimbursements for treatment 
if they ensure registration in the NPR. We used a com-
bination of the NPR [6, 11] and the DPR [8]. The entire 
group of primarily operated glioma patients is expected 
to be registered in the NPR and DPR since the neurosur-
gical procedures are centralized in a few public univer-
sity hospitals in Denmark. On the other hand, the general 
population of glioma patients may be larger because we 
have not included patients without a surgical procedure; 
i.e. not registered with a SNOMED M-code. Two Dan-
ish regional population-based studies showed that 19  % 
of the high-grade glioma patients with a dismal progno-
sis and 11 % of the low-grade glioma patients with a very 
good prognosis did not undergo surgery [12, 13].
The validity of key variables from DNOR was high. We 
selected the variables of major importance for the medi-
cal record review. A random sample of patients from all 
participating departments was identified. To standardize 
the data collection for study of validity we used the same 
assessor to monitor all the medical records from the 100 
patients. This assessor had large experience in moni-
toring medical record data from clinical trials and was 
blinded to the original DNOR data.
Data on onset symptoms, diagnostic work-up, sur-
gery and oncology treatment showed a good to excel-
lent agreement. Tumor diameter from the preoperative 
diagnostic MRI had a lower agreement (56–57 %), which 
probably was because the surgeon often made his own 
evaluation of images giving a measure different from the 
radiology report. Thus, the disagreement may be due to 
interobserver variation and thus explained by the fact 
that we used the measures from the radiology report in 
this validation study and, only if data were missing here, 
did we use the measures from the neurosurgery text of 
the medical report.
DNOR uses the Eastern Cooperative Oncology Group 
performance status score [14], which is simpler than the 
original Karnofsky performance status [15], although they 
are believed to be interchangeable [16]. Performance status 
is an important prognostic factor in patients with glioma, 
and is used in the clinical decision process. The score is 
important, regardless of possible problems with the interob-
server variability of the performance status score, which in 
other cancer studies has been rated moderate to high [16–
18]. Pre-operative performance status is reported for almost 
every patient in the DNOR. However, none of the one 
hundred patients in the validity sample had a registration 
of a score for the pre-operative performance status in the 
medical report. Therefore, it was not possible to estimate 
the validity of the pre-operative performance status. Often, 
a description of the patient performance, but not a spe-
cific score, could be identified in the medical record. In the 
future it is recommended that the performance status score 
should be included also in the neurosurgical medical report. 
The postoperative performance status score before radio-
therapy and chemotherapy showed excellent agreements.
Our study has a number of strengths. Registration in 
the DNOR is mandatory by law. The analyses were made 
at the individual level linked by the Danish national per-
sonal identification number. According to our knowledge, 
it is not possible to compare the validity of the selected 
variables in the DNOR to those in other brain tumor reg-
istries since such data on agreements have never been 
published before. However, high agreements on clinical 
variables have also been reported for other diseases in 
Danish clinical quality databases [19, 20]. Other national 
brain tumor registries, such as the Central Brain Tumor 
Registry of the United States [21] or the Austrian Brain 
Tumour Registry [22], have also reported high complete-
ness of patients, although this has not been verified by 
comparing to a gold standard population as in this study. 
Regional brain tumor registries in France [23] and Swe-
den [24] have also reported high completeness.
The patient completeness of the DNOR database and 
the validity of registered data are of crucial importance 
when using clinical quality databases as a research tool 
[25]. This study shows that DNOR has high patient reg-
istration completeness and a good validity of clinically 
important variables, making it a robust research tool. 
However, to further increase the completeness of DNOR 
there is ongoing work to make advantage of data from the 
NPR and the DPR by implementing generic algorithms 
from the Danish National Clinical Cancer Database 
workgroup. This workgroup under the Danish Clinical 
Quality Improvement Program has described proce-
dures for automated retrieval of data from the NPR and 
the DPR. In an automated process the centrally retrieved 
data are interpreted by disease specific algorithms and 
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sent to the clinicians for review to assure validation and 
supplementation of clinical data in the DNOR.
In conclusion, the completeness of the patient registra-
tion in the DNOR and the validity of clinical patient data 
was high. The DNOR is a well-established database, it is 
a reliable source for future scientific studies, and it will 
be used for ongoing clinical quality assessments among 
patients with gliomas.
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